+86 189 1304 2753 product@eynoslifescience.com

VSV-G pseudotyped lentivirus transduces HEK293T or HeLa cells above 90% without effort. Move the same vector to resting human CD34⁺ cells and efficiency collapses. The reason is not that HSCs are intrinsically refractory to lentiviral integration — it is that VSV-G enters through the LDL receptor, and LDL-receptor density is low on quiescent hematopoietic cells. Cytokine stimulation raises LDL-R expression and transduction improves, which is itself the evidence for the mechanism.

Four layers that limit efficiency

Receptor match. VSV-G binds LDL-R; low receptor density limits binding and membrane fusion.

Contact probability. Hematopoietic cells grow in suspension, so Virus–cell collisions are rare compared with adherent monolayers; spinoculation is used to compensate.

Surface charge. The glycocalyx and negative membrane charge repel the virus before entry.

Post-entry steps. Endosomal retention, reverse transcription, nuclear import and promoter silencing all reduce the final positive rate.

What envelope engineering changes

Replacing or engineering the envelope addresses the first layer directly and is the most controllable of the four. In a KG-1 model — a myeloid line reported to resist VSV-G vectors — an engineered envelope raised transduction from 22.8% to 47.4% at MOI 50 (about 2.1-fold) under otherwise identical conditions. That is a relative comparison within one model, not a promise for primary HSC; primary cells still need their own MOI and timing.

A sequence that avoids the usual mistakes

Isolate CD34⁺ cells, confirm viability above 90%, and infect on the day of isolation — no activation step is required. Run an MOI series (10 / 20 / 50) rather than a single point, keep a VSV-G control to measure the envelope effect, and read out at 24–72 hours. If the experiment ends in transplantation, keep an uninfected aliquot as the baseline and re-check the positive rate after 7–14 days: transient expression and stable integration only separate with time.

LVh34 (human CD34⁺ HSC) → · LVh45 (human CD45⁺ leukocytes) → · anti-human CD34 nanobeads →

Need a transduction baseline in your own cells?

Tell us your cell type, sample source and downstream assay — we will suggest an isolation route, a culture condition and the matching catalogue numbers.